跳转至内容
Merck
  • Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit.

Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit.

Antioxidants & redox signaling (2020-04-28)
Wisna Novera, Zheng-Wei Lee, Dawn Sijin Nin, Melvin Zi-Yu Dai, Shabana Binte Idres, Hui Wu, J Mirjam A Damen, Tuan Zea Tan, Arthur Yi Loong Sim, Yun Chau Long, Wei Wu, Ruby Yun-Ju Huang, Lih-Wen Deng
摘要

Aims: Current treatment options for ovarian clear cell carcinoma (OCCC) are limited to combination of platinum-based and other cytotoxic agents to which patients respond poorly due to intrinsic chemoresistance. There is therefore an urgent need to develop alternative therapeutic strategies for OCCC. Results: Cysteine deprivation suppresses OCCC growth in vitro and in vivo with no apparent toxicity. Modes of cell death induced by cysteine deprivation in OCCC are determined by their innate metabolic profiles. Cysteine-deprived glycolytic OCCC is abolished primarily by oxidative stress-dependent necrosis and ferroptosis, which can otherwise be prevented by pretreatment with antioxidative agents. Meanwhile, OCCC that relies on mitochondria respiration for its bioenergetics is suppressed through apoptosis, which can otherwise be averted by pretreatment with cysteine precursor alone, but not with antioxidative agents. Cysteine deprivation induces apoptosis in respiring OCCC by limiting iron-sulfur (Fe-S) cluster synthesis in the mitochondria, without which electron transport chain may be disrupted. Respiring OCCC responds to Fe-S cluster deficit by increasing iron influx into the mitochondria, which leads to iron overload, mitochondria damage, and eventual cell death. Innovation/Conclusion: This study demonstrates the importance of cysteine availability in OCCC that is for its antioxidative property and its less appreciated role in mitochondria respiration. Regardless of OCCC metabolic profiles, cysteine deprivation abolishes both glycolytic and respiring OCCC growth in vitro and in vivo. Conclusion: This study highlights the therapeutic potential of cysteine deprivation for OCCC.

材料
货号
品牌
产品描述

Sigma-Aldrich
奎诺二甲基丙烯酸酯, 97%
Sigma-Aldrich
碘化丙啶, ≥94.0% (HPLC)
Sigma-Aldrich
2',7'-二氯荧光素二乙酸酯, ≥97%
Sigma-Aldrich
谷胱甘肽还原酶 来源于面包酵母(酿酒酵母), ammonium sulfate suspension, 100-300 units/mg protein (biuret)
Sigma-Aldrich
去铁胺 甲磺酸盐, powder, ≥92.5% (TLC)
Sigma-Aldrich
N-乙酰基-L-半胱氨酸, Sigma Grade, ≥99% (TLC), powder
Sigma-Aldrich
(R)-MG132
Sigma-Aldrich
硫酸亚铁(II)铵 六水合物, 99.997% trace metals basis
Sigma-Aldrich
2,2′-联吡啶, ReagentPlus®, ≥99%
Sigma-Aldrich
茚三酮, ACS reagent
Sigma-Aldrich
DL-炔丙基甘氨酸, cystathionine γ-lyase inhibitor
Sigma-Aldrich
D -莱氏乳杆菌乳酸脱氢酶, lyophilized powder, 150-500 units/mg protein
Sigma-Aldrich
异柠檬脱氢酶 (NADP) 来源于猪心脏, Type I, 0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)
Sigma-Aldrich
柳氮磺胺吡啶, 97.0-101.5%
Sigma-Aldrich
Amyloid Protein Non-Aβ Component, ≥80% (HPLC)